VBI Vaccines completes vaccination in PROTECT phase 3 clinical study for Sci-B-Vac®
VBI Vaccines announced the last subject has received the last vaccination in the PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation prophylactic hepatitis B vaccine. Top-line data from this study are expected mid-2019. October 16, 2018